rrt2 Antibody

What is the MHT2 antibody and what epitope does it recognize?

MHT2 is a monoclonal antibody that specifically recognizes human tau protein around the T169/T175 region. It was generated using a synthetic peptide comprised of residues 163-179 of the human tau protein with phosphorylation at T175 as the immunizing antigen . Importantly, this antibody shows specificity for human tau over murine tau, likely due to amino acid differences between human and mouse tau at positions 165 and 166 within this epitope region . The antibody appears to recognize the tau epitope represented by the 163-179 amino acid sequence but does not specifically recognize phosphorylation at the T175 site .

How does phosphorylation affect antibody recognition of tau epitopes?

Phosphorylation can significantly alter antibody recognition of tau epitopes. In the case of the MHT2 antibody, ELISA data suggests that phosphorylation at T169 appears to mitigate MHT2 activity . This reduction in activity when T169 is phosphorylated indicates that this site is important for the recognition of tau by the antibody . This highlights the critical importance of understanding post-translational modifications when designing and utilizing antibodies against tau protein. Researchers should carefully consider how phosphorylation states may affect epitope recognition when selecting antibodies for specific experimental applications.

What controls should be implemented when characterizing new tau antibodies?

When characterizing new tau antibodies, proper controls are essential to ensure specificity and reliability. The research on MHT1 and MHT2 antibodies demonstrates the importance of these controls:

• Peptide competition assays: Testing antibody binding to both phosphorylated and non-phosphorylated peptides to confirm epitope specificity

• Western blot analysis using:

  • Recombinant protein expression systems (e.g., HEK293T cells)

  • Brain lysates from tau knockout mice as negative controls

  • Brain lysates from tau overexpression models (e.g., rTg4510 mice)

• Comparison with established tau antibodies (e.g., PHF1) in parallel experiments

• Testing across multiple experimental platforms (ELISA, Western blot, immunohistochemistry)

The MHT1 antibody case is particularly instructive, as it recognized non-tau proteins approximately 20 kD and 55 kD in size, emphasizing the importance of proper negative controls in antibody characterization .

How does the conformational state of tau affect antibody recognition in different stages of tauopathy?

The conformational state of tau protein significantly impacts antibody recognition, particularly as tauopathy progresses. The MHT2 antibody demonstrates interesting stage-dependent recognition patterns:

• In early-stage tauopathy (rTg4510 mice younger than 6 months), MHT2 shows minimal immunoreactivity despite the presence of tau pathology that is detectable with other antibodies like PHF1

• MHT2 signal becomes readily apparent starting at 6 months of age in rTg4510 mice

• MHT2 recognition of neurofibrillary tangles (NFTs) appears to match PHF1 staining only at later stages (8.5+ months)

This suggests either:

• A progressive, age-dependent decrease in phosphorylation at T169, which appears to enhance MHT2 binding

• The MHT2-targeted epitope may be conformationally unavailable under normal physiological conditions, but becomes accessible in later-stage tau pathology

These findings suggest that MHT2 may have conformational specificity, preferentially recognizing fully developed, somatic NFTs rather than early-stage tau aggregates or pathological tau in neurites .

What methodological approaches should be used when designing antibodies against specific tau phospho-epitopes?

Based on the experiences with generating antibodies against LRRK2-targeted tau epitopes, researchers should consider these methodological approaches:

• Peptide design considerations:

  • Peptide length is critical - initial attempts with shorter peptides (163-176 and 165-176) failed to generate antibodies against phosphorylated T169

  • Expanded peptide length (163-179) proved successful for generating hybridomas

  • Include adequate flanking sequences around the phosphorylation site of interest

• Screening strategy progression:

  • Begin with ELISA screening against multiple peptide variants (phosphorylated and non-phosphorylated)

  • Perform Western blot validation using recombinant proteins and tissue lysates

  • Conduct immunohistochemical validation in relevant disease models

  • Compare with established antibodies targeting known phospho-epitopes

• Epitope accessibility assessment:

  • Test antibodies against both soluble and insoluble tau fractions

  • Evaluate recognition patterns across developmental timepoints in tauopathy models

  • Consider testing with different tissue preparation methods to account for conformation-dependent epitope masking

How can species-specific antibodies like MHT2 be utilized in transgenic mouse models of tauopathy?

Species-specific antibodies like MHT2, which recognizes human but not murine tau, offer unique advantages in transgenic mouse models:

• Selective tracking of human transgenic tau:

  • MHT2 allows specific visualization of human tau in transgenic models without detecting endogenous mouse tau

  • This enables clear differentiation between transgene-derived pathology and endogenous tau

• Experimental applications:

  • Differential analysis of human vs. mouse tau in co-expression models

  • Tracking human tau propagation in seeding/spreading experiments

  • Comparing pathological progression between human tau and murine tau

• Methodological considerations:

  • Western blot analysis shows MHT2 detects human tau in rTg4510 mice but not tau in non-transgenic mice

  • When using species-specific antibodies, researchers should include appropriate controls (human tau-expressing and non-transgenic samples)

  • Consider epitope masking that may occur in different fixation or tissue preparation methods

What are the differences in subcellular tau pathology detection between antibodies like MHT2 and PHF1?

Different tau antibodies can reveal distinct aspects of subcellular tau pathology distribution:

The MHT2 antibody appears to recognize only somatic, cytoplasmic tau, while the PHF1 antibody recognizes pathology in both cell bodies and neurites . This differential recognition pattern suggests that:

• Different tau epitopes may be exposed at varying stages of aggregation

• The conformation of tau may differ between cell compartments

• Post-translational modifications may vary spatially within neurons

Researchers should consider using multiple antibodies targeting different epitopes to obtain a comprehensive view of tau pathology distribution.

What methodological challenges exist in producing phosphorylation-specific antibodies against tau?

Producing phosphorylation-specific antibodies against tau presents several methodological challenges as evidenced by the attempts to create antibodies against phosphorylated T169 and T175:

• Epitope design considerations:

  • Initial attempts using shorter peptides (165-176 and 163-176) with phosphorylated T169 were unsuccessful

  • Success was achieved only after expanding to longer peptides (163-179)

  • The positioning of the phosphorylation site within the peptide may affect immunogenicity

• Phospho-specificity challenges:

  • Despite successfully generating antibodies using phosphorylated peptides, neither MHT1 nor MHT2 showed true phospho-specificity

  • The antibodies recognized the tau epitope but did not specifically detect phosphorylation at the intended sites

  • Reduction in antibody activity when certain sites were phosphorylated indicates that phosphorylation may actually hinder recognition

• Validation requirements:

  • Comprehensive testing against multiple phosphorylated and non-phosphorylated peptide variants is essential

  • Cross-reactivity testing against other phosphoproteins should be included

  • Functional validation in disease models where phosphorylation states change dynamically

These challenges highlight why phosphorylation-specific antibodies against many tau epitopes remain elusive despite their importance for understanding tau pathophysiology.

How can tau-specific antibodies contribute to tracking disease progression in tauopathies?

Tau-specific antibodies can serve as valuable tools for tracking disease progression in tauopathies through various approaches:

• Stage-specific recognition patterns:

  • The MHT2 antibody exhibits age-dependent staining in rTg4510 mice, with signal becoming apparent only at 6 months and matching PHF1 staining at 8.5+ months

  • This suggests MHT2 may recognize conformational changes or epitope accessibility that occurs specifically in later-stage pathology

• Methodology for disease staging:

  • Use multiple antibodies recognizing different tau epitopes to create a temporal map of pathology progression

  • Compare staining patterns between early markers (like PHF1) and late markers (like MHT2) to determine disease stage

  • Correlate antibody reactivity patterns with functional outcomes to establish clinical relevance

• Applications in experimental models:

  • Track the transition from early to late stage pathology in interventional studies

  • Evaluate whether therapeutic compounds affect specific aspects of tau pathology recognized by different antibodies

  • Use species-specific antibodies like MHT2 to distinguish human tau pathology from murine tau in transgenic models

What considerations should researchers address when evaluating new tau-targeted antibodies for potential therapeutic applications?

When evaluating new tau-targeted antibodies for potential therapeutic applications, researchers should address several key considerations:

• Epitope specificity and accessibility:

  • Determine whether the epitope is accessible in pathological tau conformations in vivo

  • Assess whether the epitope is present in various tau isoforms and post-translationally modified forms

  • The MHT2 example shows epitopes may be differentially accessible depending on disease stage or tau conformation

• Species cross-reactivity:

  • Evaluate cross-reactivity between human and animal tau proteins, as this affects translational research

  • MHT2 specifically recognizes human tau but not murine tau due to amino acid differences at positions 165 and 166

  • Consider how species differences might influence preclinical testing results

• Pathological selectivity:

  • Determine whether the antibody distinguishes between normal and pathological tau

  • Assess recognition of different tau aggregate species (oligomers, paired helical filaments, straight filaments)

  • MHT2 appears to recognize fully developed NFTs rather than early-stage aggregates, suggesting potential specificity for advanced pathology

• Technical validation requirements:

  • Perform comprehensive binding studies against recombinant tau and brain-derived tau

  • Validate findings across multiple experimental platforms and disease models

  • Include appropriate controls such as tau knockout tissues

What experimental protocols should be followed when validating novel tau antibodies?

A comprehensive antibody validation protocol should include:

• Initial characterization:

  • ELISA testing against multiple peptide variants (phosphorylated and non-phosphorylated) to determine epitope specificity

  • Peptide competition assays to confirm binding specificity

  • Determine optimal antibody concentration for different applications

• Protein-level validation:

  • Western blot analysis using:

    • Recombinant tau protein (wild-type and mutant variants)

    • Cell lysates from tau-expressing and control cells

    • Brain lysates from transgenic models, non-transgenic controls, and tau knockout animals

  • Assess recognition of different tau isoforms and post-translationally modified forms

• Tissue-level validation:

  • Immunohistochemistry on:

    • Transgenic mouse models at different disease stages (as demonstrated with rTg4510 mice)

    • Human brain tissue from control subjects and tauopathy patients

  • Compare staining patterns with established tau antibodies like PHF1

  • Test different fixation and tissue preparation methods to optimize epitope accessibility

• Functional validation:

  • Immunoprecipitation to confirm pull-down of tau protein

  • Assess ability to neutralize tau pathology in cellular or animal models

  • Evaluate developmental timeline of antibody reactivity in progressive disease models

The MHT2 antibody case study demonstrates the importance of thorough validation across multiple experimental platforms to fully characterize antibody properties and potential limitations .